Published Data Show Why GSK Bailed on Its Maternal RSV Vaccine
GSK’s abandoned maternal respiratory syncytial virus (RSV) vaccine protected infants from severe RSV, final results of a phase III trial indicated, but those positive outcomes came at the expense of an unexplained higher risk for preterm birth. For newborns up to 6 months of age, efficacy with the RSV prefusion F protein-based vaccine (RSVPreF3-Mat) during […]
Is Exercising When You’re Sick Safe Or Can It Help? Experts Weigh In.
LOADINGERROR LOADING Questions about the safety of working out when sick with an upper respiratory infection are a common concern, according to doctors. Many folks pressure themselves to exercise even when they aren’t feeling 100% well — or hope a good workout will help sweat out their illness. (Spoiler alert: It won’t.) It is frustrating […]
Respiratory Syncytial Virus (RSV) Definition, Symptoms, Treatment, Transmission
Facts you should know about respiratory syncytial virus (RSV) infection Respiratory Viral Infections RSV is a highly contagious virus infection that is most prevalent during the winter season. Most children who develop an RSV infection have mild symptoms of fever, nasal congestion, nasal discharge, and cough. High-risk groups are more likely to have a more […]
Is Respiratory Syncytial Virus (RSV) Contagious?
Is respiratory syncytial virus (RSV) contagious? Respiratory syncytial virus (RSV) is contagious. In the United States, it’s the most common cause of inflammation of the small airways in the lungs (bronchiolitis) and of pneumonia in children under 1 year of age. It also is significant cause of respiratory illnesses in older adults. Nearly all children […]
RSV Vaccine Benefits Probably Outweigh Small Neurologic Risk, CDC Advisors Say
The benefits of vaccination against respiratory syncytial virus (RSV) for adults ages 60 and older probably outweigh the small risk of vaccine-related Guillain-Barré syndrome (GBS), the CDC’s Advisory Committee on Immunization Practices (ACIP) reaffirmed. In a presentation on the second day of the ACIP’s 2-day meeting, Amadea Britton, MD, of the CDC’s RSV adult vaccination […]
Bivalent Vax Protected Kids From Symptomatic COVID
During the 2022-2023 respiratory season, the bivalent COVID vaccines had an effectiveness of 54% against infection and 49% against symptomatic COVID in children and adolescents ages 5 to 17 years, a new study in JAMA showed. In this interview, Melissa Briggs Hagen, MD, MPH, of the CDC’s Coronavirus and Other Respiratory Viruses Division, discusses the […]
Nirsevimab Reduced Hospitalizations for Infants With RSV
The monoclonal antibody nirsevimab (Beyfortus) reduced hospitalizations among infants with respiratory syncytial virus (RSV)-associated lower respiratory tract infection, the randomized, pragmatic HARMONIE trial showed. In over 8,000 infants included in the study, 0.3% who received nirsevimab were hospitalized for RSV-associated lower respiratory tract infection compared with 1.5% of those who received standard care, which corresponded […]
Moderna’s mRNA RSV Vaccine Effective in Older Adults
Moderna’s mRNA-based RSV vaccine was effective at preventing RSV-associated lower respiratory tract disease in adults ages 60 and older, according to results of the randomized ConquerRSV trial. The mRNA-1345 vaccine was 83.7% effective (95.88% CI 66%-92.2%) in preventing RSV-associated lower respiratory tract disease with at least two signs or symptoms, and similarly effective (82.4%) against […]
Prone Positioning Falls Flat for Weaning COVID Patients Off ECMO
Early application of prone positioning did not help patients with severe acute respiratory distress syndrome (ARDS) — mostly from COVID — get off venovenous extracorporeal membrane oxygenation (VV-ECMO) any faster compared to supine positioning, a randomized trial found. Among ARDS patients receiving ECMO, an identical 44% of patients were successfully weaned off ECMO after 60 […]
Convalescent Plasma Improves Survival in COVID Patients with ARDS, New Trial Shows
Convalescent plasma reduced mortality in COVID-19 patients with acute respiratory distress syndrome (ARDS) when provided within 5 days of invasive mechanical ventilation, the randomized open-label CONFIDENT trial showed. Mortality at 28 days was 35.4% among patients who received donated convalescent plasma with at least 1:160 neutralizing antibody titer, compared with 45% in patients who received […]